*PEOPLE: ROTH Adds to Healthcare Research Team
ROTH Capital Partners, a full-service investment bank focused on serving emerging growth companies and their investors, today announced that Jerry Isaacson has joined the firm’s healthcare research team.
Isaacson will serve as a managing director and senior research analyst covering biotech and emerging therapeutics.
He has a broad range of experience covering companies in many different disease areas, as well as medical devices and diagnostics. His specialty is anti-infectives, gene therapy, and oncology.
Prior to joining ROTH, he spent seven years leading the research group of LifeSci Capital, where he built the research team from the ground up and initiated coverage on more than 100 companies.
Before that, he was an editor at the Medical Technology Stock Letter, primarily covering oncology and diabetes companies.
His previous experience includes work in the biotech industry, where he served in various roles ranging from analytical and medicinal chemistry to corporate communications and writing patents.
He got his Ph.D. in organic chemistry at UCSD, conducting total synthesis of natural products and received his B.A. degree in chemistry from Harvard University.
“The recent emergence of new treatment modalities, as well as genomic and diagnostic tools makes this a very exciting time in the biotechnology arena for patients, physicians, drug developers, and investors,” Isaacson said in a press release issued today.